Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials
Akbar D, Rhee T, Ceban F, Ho R, Teopiz K, Cao B, Subramaniapillai M, Kwan A, Rosenblat J, McIntyre R. Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials. CNS Drugs 2023, 37: 867-881. PMID: 37792265, DOI: 10.1007/s40263-023-01032-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsBupropionClinical Trials as TopicDepressionDepressive Disorder, MajorDextromethorphanHumansConceptsMajor depressive disorderPathophysiology of MDDSystematic reviewMontgomery-Åsberg Depression Rating ScaleNMDA receptor antagonist dextromethorphanTransient adverse eventsRisk of biasDepression Rating ScaleMonoamine-based antidepressantsTreatment of depressionBackgroundA significant proportionPlacebo control groupCombination of dextromethorphanMechanism of actionConclusionCurrent evidenceClinical remissionAdverse eventsCochrane riskBias toolDatabase inceptionTreatment optionsScore reductionClinical trialsDepressive disorderActive control group